Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.87 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.73 |
| ▸ | CIT | O14578 | 1/20 | 0.73 |
| ▸ | GAK | O14976 | 1/20 | 0.73 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.73 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.73 |
| ▸ | STK10 | O94804 | 1/20 | 0.73 |
| ▸ | ABL1 | P00519 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | MET | P08581 | 1/20 | 0.73 |
| ▸ | HCK | P08631 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.73 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.73 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.73 |
| ▸ | AXL | P30530 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30101593 | 1.00 | EGFR (0.87) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL17538538 | 0.93 | EGFR (1.00) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL867638 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL867639 | 0.93 | EGFR (0.85) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL20325402 | 0.93 | EGFR (0.83) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL17538473 | 0.92 | EGFR (1.00) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL25859410 | 0.92 | EGFR (0.78) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL19639023 | 0.92 | EGFR (0.74) | EGFRERBB2ERBB4CITGAK | |
| SCHEMBL23154276 | 0.91 | EGFR (0.77) | EGFRERBB2ERBB4JAK3 | |
| SCHEMBL25859411 | 0.91 | EGFR (0.77) | EGFRERBB2ERBB4JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111297865-A | Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| CN-111297865-A | Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| US-10668069-B2 | Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSITUTE CO., LTD (CN) | 2020-06-02 | — | — | US | disclosed |
| US-10668069-B2 | Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSITUTE CO., LTD (CN) | 2020-06-02 | — | — | US | disclosed |
| US-20190224201-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NEPTINIB OR SALT THEREOF AND METHOD FOR CONTROLLING IMPURITY THEREOF | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| US-20190224201-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NEPTINIB OR SALT THEREOF AND METHOD FOR CONTROLLING IMPURITY THEREOF | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2019-07-25 | — | — | US | disclosed |
| US-9957237-B2 | Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-9957237-B2 | Crystal form of neptinib di-p-methylbenzenesulfonate, preparation method thereof, and pharmaceutical composition containing same | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2018-05-01 | — | — | US | disclosed |
| US-20170342037-A1 | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
| US-20170342037-A1 | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | SHENZHEN NEPTUNUS PHARMACEUTICAL RESEARCH INSTITUTE CO., LTD. (CN) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342037-A1 | A CRYSTAL FORM OF NEPTINIB di-P-METHYLBENZENESULFONATE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | ABL1, NEK5, CYP2D6 | EGFR 252/4885ERBB2 874/4885ERBB4 617/4885 |
| US-10668069-B2 | Pharmaceutical composition comprising neptinib or salt thereof and method for controlling impurity thereof | NEK5, NEK9, MME | EGFR 51/4885ERBB2 597/4885ERBB4 627/4885 |
| US-20190224201-A1 | PHARMACEUTICAL COMPOSITION COMPRISING NEPTINIB OR SALT THEREOF AND METHOD FOR CONTROLLING IMPURITY THEREOF | NEK5, NEK9, MME | EGFR 51/4885ERBB2 597/4885ERBB4 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.